Former FDA commissioner Scott Gottlieb said July 26 that Taylor Farms' decision to contact the White House seeking to delay a recall announcement tied to a cyclospora outbreak was "not standard operating procedure" during his tenure at the agency, adding his voice to a controversy that has drawn scrutiny to the intersection of food-safety regulation and political intervention.

Cyclospora is a microscopic parasite that causes an intestinal illness called cyclosporiasis, typically contracted from contaminated food or water. Outbreaks linked to fresh produce are not uncommon in the U.S., but the scale of this one has been significant.

Speaking on CBS's Face the Nation with host Margaret Brennan, Gottlieb was asked about a Wall Street Journal report that Taylor Farms contacted the Trump White House requesting more time before the government publicly linked the company to the outbreak. According to The Guardian's summary of the WSJ report, the White House then asked FDA officials to join the call with Taylor Farms The Guardian.

"I dealt with outbreaks in romaine lettuce and spinach as well, E coli in spinach and romaine lettuce," Gottlieb said. "I never heard from the White House on those things, other than to have discussions to inform them of what we were doing, so that they were properly briefed and could respond to questions that they were getting" CBS News. He characterized the Taylor Farms situation as "unusual" and said the company's approach was "not standard operating procedure when I was at FDA" either.

The WSJ, which broke the story on July 24, reported that Taylor Farms sought the meeting after executives believed they had not received sufficient clarity from the FDA about the evidence supporting a potential recall and its scope WSJ. During the call, Taylor Farms argued that federal investigators lacked positive laboratory evidence connecting its products to the outbreak and expressed concerns the government was overstating the company's responsibility.

That evidentiary question became more complicated on July 20, when the WSJ reported that the FDA had walked back its earlier finding that a sample of lettuce from Taylor Farms tested positive for cyclospora WSJ. Taylor Farms' recall remained in place. The FDA stated that the false-positive test result does not affect the outbreak conclusions Reuters.

The outbreak itself has been substantial. Cyclospora sickened at least 1,645 people in the U.S. in 2026, according to AP reporting AP News. Michigan alone reported over 6,000 cyclosporiasis cases by July 20 Reuters. The CDC expanded its outbreak investigation to four additional states, the WSJ reported July 24 WSJ.

Taylor Farms, described by the WSJ as a global salad giant, recalled 25 shredded lettuce and salad mix products sold under eight different brand codes, expanding the recall to 27 states AP News. Taco Bell lettuce supplied by Taylor Farms was linked to the outbreak WSJ. Sysco separately pulled iceberg lettuce from central Mexico linked to the U.S. cyclosporiasis outbreak Reuters.

The broader context here is a structural question about how food-safety governance works when a company disagrees with the agency overseeing it. Normally, the FDA works directly with a company it suspects is linked to an outbreak, presenting evidence and negotiating the scope of a recall. In this case, Taylor Farms escalated beyond the agency to the White House, the political leadership that sits above the FDA. Gottlieb's comments frame that move as outside the norm he experienced, while the FDA's retraction of its positive test result adds weight to the company's contention that the evidence was not airtight. Yet the recall held, and the outbreak conclusions stood.

The tension between those two facts — a retracted lab finding and a sustained recall — is where the policy stakes concentrate. If the FDA's epidemiological case can hold without the lab confirmation it initially claimed, that speaks to the strength of the broader investigative framework, which often relies on pattern-matching across reported illnesses rather than a single contaminated sample. But it also means a company's argument that investigators overstated their evidence can be simultaneously true in part and insufficient to alter the regulatory outcome. For food-industry compliance professionals and public-health officials, the episode is a case study in how evidentiary disputes during an active outbreak can move from technical disagreement to political escalation, and in what the norms are, or were, when they do.